Patents by Inventor Takatoshi Yogo

Takatoshi Yogo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210163934
    Abstract: The object of the present invention is to provide a nucleic acid agent that can be efficiently delivered to the nervous system, particularly the central nervous system to which the BBB mechanism prevents drug delivery, and can produce an antisense effect on a target transcriptional product at the delivered site, and a composition comprising the same. Provided is a double-stranded nucleic acid complex formed by annealing a first nucleic acid strand capable of hybridizing to part of a target transcriptional product, and has an antisense effect on the target transcriptional product, to a second nucleic acid strand comprising a base sequence complementary to the first nucleic acid strand, and is bound to tocopherol or an analog thereof, cholesterol or an analog thereof, or a substituted or unsubstituted C1-30 alkyl group, a substituted or unsubstituted C2-30 alkenyl group, or a substituted or unsubstituted C1-30 alkoxy group.
    Type: Application
    Filed: March 22, 2019
    Publication date: June 3, 2021
    Applicant: NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY
    Inventors: Takanori YOKOTA, Tetsuya NAGATA, Hideki FURUKAWA, Yasuo NAKAGAWA, Takatoshi YOGO, Ryosuke TOKUNOH, Shigekazu SASAKI, Kosuke HIDAKA, Tomohiro SEKI, Kenichi MIYATA, Yusuke ADACHI, Naoto ARIMURA
  • Publication number: 20210024929
    Abstract: Developed and provided is: a nucleic acid agent that is efficiently delivered to the central nervous system, to which drug delivery is inhibited by the blood brain barrier mechanism, and that provides an antisense effect to a target transcription product at the delivery site; and a composition containing such a nucleic acid agent. Provided is a double-stranded nucleic acid complex consisting of a first nucleic acid strand and a second nucleic acid strand that are annealed to each other; wherein the first nucleic acid strand hybridizes with part of a target transcription product and has an antisense effect on the target transcription product; and wherein the second nucleic acid strand includes a base sequence complementary to the first nucleic acid strand and is conjugated to a phosphatidylethanolamine or an analog thereof.
    Type: Application
    Filed: March 13, 2019
    Publication date: January 28, 2021
    Applicants: National University Corporation Tokyo Medical and Dental University, Takeda Pharmaceutical Company Limited
    Inventors: Takanori Yokota, Tetsuya Nagata, Hideki Furukawa, Yasuo Nakagawa, Takatoshi Yogo, Ryosuke Tokunoh, Shigekazu Sasaki, Kosuke Hidaka, Tomohiro Seki, Kenichi Miyata, Akio Uchida
  • Patent number: 10787462
    Abstract: The present invention provides a heterocyclic compound having an RIP1 kinase inhibitory action, which is useful for the prophylaxis or treatment of Gaucher's disease, Niemann-Pick disease, inflammatory bowel disease, multiple sclerosis, chronic kidney disease, acute kidney injury, acute hepatic failure, autoimmune hepatitis, hepatitis B, hepatitis C, alcohol steatohepatitis, non-alcohol steatohepatitis and the like. The present invention relates to a compound represented by the following formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Grant
    Filed: October 21, 2016
    Date of Patent: September 29, 2020
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Takatoshi Yogo, Masato Yoshikawa, Morihisa Saitoh, Taisuke Katoh, Tomohiro Seki, Yoshihisa Nakada
  • Publication number: 20180319819
    Abstract: The present invention provides a heterocyclic compound having an RIP1 kinase inhibitory action, which is useful for the prophylaxis or treatment of Gaucher's disease, Niemann-Pick disease, inflammatory bowel disease, multiple sclerosis, chronic kidney disease, acute kidney injury, acute hepatic failure, autoimmune hepatitis, hepatitis B, hepatitis C, alcohol steatohepatitis, non-alcohol steatohepatitis and the like. The present invention relates to a compound represented by the following formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Application
    Filed: October 21, 2016
    Publication date: November 8, 2018
    Inventors: Takatoshi YOGO, Masato YOSHIKAWA, Morihisa SAITOH, Taisuke KATOH, Tomohiro SEKI, Yoshihisa NAKADA
  • Publication number: 20170174682
    Abstract: Provided is a compound or a salt thereof, which has an excellent JAK inhibitory action, and is useful as a prophylactic or therapeutic agent for autoimmune diseases (rheumatoid arthritis, psoriasis, inflammatory bowel disease, Sjogren's syndrome, Behcet's syndrome, multiple sclerosis, systemic lupus erythematosus, etc.), cancer (leukemia, uterine leiomyosarcoma, prostate cancer, multiple myeloma, cachexia, myelofibrosis, etc.) and the like. The present invention relates to a compound represented by the formula (I) wherein each symbol is as defined in the present specification, or a salt thereof.
    Type: Application
    Filed: March 7, 2017
    Publication date: June 22, 2017
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Masato YOSHIDA, Hiroyuki NAGAMIYA, Yusuke OHBA, Masaki SETO, Takatoshi YOGO, Satoshi SASAKI, Norihito TOKUNAGA, Kazuyoshi ASO
  • Patent number: 9637483
    Abstract: Provided is a compound or a salt thereof, which has an excellent JAK inhibitory action, and is useful as a prophylactic or therapeutic agent for autoimmune diseases (rheumatoid arthritis, psoriasis, inflammatory bowel disease, Sjogren's syndrome, Behcet's syndrome, multiple sclerosis, systemic lupus erythematosus, etc.), cancer (leukemia, uterine leiomyosarcoma, prostate cancer, multiple myeloma, cachexia, myelofibrosis, etc.) and the like. The present invention relates to a compound represented by the formula (I) wherein each symbol is as defined in the present specification, or a salt thereof.
    Type: Grant
    Filed: March 27, 2014
    Date of Patent: May 2, 2017
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Masato Yoshida, Hiroyuki Nagamiya, Yusuke Ohba, Masaki Seto, Takatoshi Yogo, Satoshi Sasaki, Norihito Tokunaga, Kazuyoshi Aso
  • Publication number: 20160159773
    Abstract: The present invention provides an agent for the prophylaxis or treatment of autoimmune diseases (e.g., psoriasis, rheumatoid arthritis, inflammatory bowel disease, Sjogren's syndrome, Behcet's disease, multiple sclerosis, systemic lupus erythematosus etc.) and the like, which has a superior Tyk2 inhibitory action. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Application
    Filed: July 29, 2014
    Publication date: June 9, 2016
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Morihisa Saitoh, Takatoshi Yogo, Taku Kamei, Norihito Tokunaga, Yusuke Ohba, Takafumi Yukawa
  • Publication number: 20160039811
    Abstract: Provided is a compound or a salt thereof, which has an excellent JAK inhibitory action, and is useful as a prophylactic or therapeutic agent for autoimmune diseases (rheumatoid arthritis, psoriasis, inflammatory bowel disease, Sjogren's syndrome, Behcet's syndrome, multiple sclerosis, systemic lupus erythematosus, etc.), cancer (leukemia, uterine leiomyosarcoma, prostate cancer, multiple myeloma, cachexia, myelofibrosis, etc.) and the like. The present invention relates to a compound represented by the formula (I) wherein each symbol is as defined in the present specification, or a salt thereof.
    Type: Application
    Filed: March 27, 2014
    Publication date: February 11, 2016
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Masato YOSHIDA, Hiroyuki NAGAMIYA, Yusuke OHBA, Masaki SETO, Takatoshi YOGO, Satoshi SASAKI, Norihito TOKUNAGA, Kazuyoshi ASO
  • Patent number: 9085578
    Abstract: The present invention provides an agent for the prophylaxis or treatment of autoimmune diseases (e.g., psoriasis, rheumatoid arthritis, inflammatory bowel disease, Sjogren's syndrome, Behcet's disease, multiple sclerosis, systemic lupus erythematosus etc.) and the like, which has a superior Tyk2 inhibitory action. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Grant
    Filed: February 19, 2013
    Date of Patent: July 21, 2015
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Hiroyuki Nagamiya, Masato Yoshida, Masaki Seto, Shogo Marui, Tsuneo Oda, Yuji Ishichi, Hideo Suzuki, Tomokazu Kusumoto, Takatoshi Yogo, Chul Yun Rhim, Cheolhwan Yoon, Gil Nam Lee, Hyun Bin Kang, Kwang Ok Kim, Hye Sun Jeon
  • Patent number: 9073864
    Abstract: Provided is an aromatic ring compound having a glucagon antagonistic action, which is useful for the prophylaxis or treatment of diabetes and the like. A compound represented by the formula (I): wherein each symbol is as defined in the DESCRIPTION, or a salt thereof has a superior glucagon antagonistic action, and is useful as a glucagon antagonist, a glucose production inhibitor or an agent for the prophylaxis or treatment of diabetes and the like.
    Type: Grant
    Filed: March 28, 2013
    Date of Patent: July 7, 2015
    Assignee: Takeda Pharmaceutical Company Limted
    Inventors: Minoru Sasaki, Hideki Furukawa, Kousuke Hidaka, Kyoko Toyofuku, Takatoshi Yogo, Toshiki Murata
  • Publication number: 20150152052
    Abstract: Provided is an aromatic ring compound having a glucagon antagonistic action, which is useful for the prophylaxis or treatment of diabetes and the like. A compound represented by the formula (I): wherein each symbol is as defined in the DESCRIPTION, or a salt thereof has a superior glucagon antagonistic action, and is useful as a glucagon antagonist, a glucose production inhibitor or an agent for the prophylaxis or treatment of diabetes and the like.
    Type: Application
    Filed: March 28, 2013
    Publication date: June 4, 2015
    Inventors: Minoru Sasaki, Hideki Furukawa, Kousuke Hidaka, Kyoko Toyofuku, Takatoshi Yogo, Toshiki Murata
  • Publication number: 20150045349
    Abstract: The present invention provides an agent for the prophylaxis or treatment of autoimmune diseases (e.g., psoriasis, rheumatoid arthritis, inflammatory bowel disease, Sjogren's syndrome, Behcet's disease, multiple sclerosis, systemic lupus erythematosus etc.) and the like, which has a superior Tyk2 inhibitory action. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Application
    Filed: February 19, 2013
    Publication date: February 12, 2015
    Inventors: Hiroyuki Nagamiya, Masato Yoshida, Masaki Seto, Shogo Marui, Tsuneo Oda, Yuji Ishichi, Hideo Suzuki, Tomokazu Kusumoto, Takatoshi Yogo, Chul Yun Rhim, Cheolhwan Yoon, Gil Nam Lee, Hyun Bin Kang, Kwang Ok Kim, Hye Sun Jeon